Alkermes
advancing across key domains submission of data for presentation at upcoming congresses artistry updated safety and efficacy data artistry dose and initial efficacy and safety data advance ongoing studies advance interactions with regulatory authorities initiate studies in mucosal melanoma and platinum resistant ovarian cancer to support potential registration pursue strategic collaborations to expand development program | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
82 of 144
Related slides by other companies
Kymera
Results
December 2022
interim safety data summary | Kymera
Oculis
Investor Presentation
July 2023
efficacy and safety of ophthalmic suspension eye drops in uveitic and post surgical macular edema the leopard study leopard | Oculis
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io